Literature DB >> 19261750

Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway.

B Cui1, S P Johnson, N Bullock, F Ali-Osman, D D Bigner, H S Friedman.   

Abstract

The presence of DNA damage initiates signaling through the ataxia-telangiectasia mutated kinase (ATM) and the ATM- and the Rad3-related kinase (ATR), which phosphorylate, thus activating, the checkpoint kinases (Chk) 1 and 2, which leads to cell cycle arrest. The bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is cytotoxic primarily by inducing DNA monoadducts and ultimately, interstrand cross-links, which block DNA replication. In this study, we investigated the activation of the ATR-Chk1 pathway in response to BCNU treatment and the dependence of this response on the DNA mismatch repair (MMR) capacity. Medulloblastoma cells were exposed to low and moderate doses of BCNU, and the effects on this DNA damage signaling pathway were examined. In response to BCNU, Chk1 was found to be phosphorylated at serine 345 and exhibited increased kinase activity. Caffeine and wortmannin, which are broad-spectrum inhibitors of ATM and ATR, reduced this phosphorylation. Cell cycle analysis further revealed an accumulation of cells in the S phase in response to BCNU, an effect that was attenuated by caffeine. Small interfering RNA knockdown of ATR also reduced Chk1 phosphorylation after exposure to BCNU. However, knockdown of ATM had no effect on the observed Chk1 phosphorylation, suggesting that ATR was primarily responsible for Chk1 activation. Analysis of Chk1 activation in cells deficient in MMR proteins MutLalpha or MutSalpha indicated that the DNA damage response induced by BCNU was independent of the MMR apparatus. This MMR-independent activation seems to be the result of DNA interstrand cross-link formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261750      PMCID: PMC2684885          DOI: 10.1124/mol.108.053124

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells.

Authors:  R D Johnson; M Jasin
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function.

Authors:  William A Cliby; Kriste A Lewis; Kia K Lilly; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2001-11-07       Impact factor: 5.157

3.  DNA replication is required To elicit cellular responses to psoralen-induced DNA interstrand cross-links.

Authors:  Y M Akkari; R L Bateman; C A Reifsteck; S B Olson; M Grompe
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

4.  Mismatch repair, G(2)/M cell cycle arrest and lethality after DNA damage.

Authors:  G Aquilina; M Crescenzi; M Bignami
Journal:  Carcinogenesis       Date:  1999-12       Impact factor: 4.944

5.  ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1.

Authors:  H Zhao; H Piwnica-Worms
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

6.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors:  M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

7.  Direct demonstration in synthetic oligonucleotides that N,N'-bis(2-chloroethyl)-nitrosourea cross links N1 of deoxyguanosine to N3 of deoxycytidine on opposite strands of duplex DNA.

Authors:  P L Fischhaber; A S Gall; J A Duncan; P B Hopkins
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

8.  Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine.

Authors:  J N Sarkaria; E C Busby; R S Tibbetts; P Roos; Y Taya; L M Karnitz; R T Abraham
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

Review 9.  Repair of O(6)-alkylguanine by alkyltransferases.

Authors:  A E Pegg
Journal:  Mutat Res       Date:  2000-04       Impact factor: 2.433

10.  Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2.

Authors:  Aaron W Adamson; Dillon I Beardsley; Wan-Ju Kim; Yajuan Gao; R Baskaran; Kevin D Brown
Journal:  Mol Biol Cell       Date:  2005-01-12       Impact factor: 4.138

View more
  10 in total

1.  HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  Genglin Jin; Stephen Cook; Bo Cui; William C Chen; Stephen T Keir; Patrick Killela; Chunhui Di; Cathy A Payne; Simon G Gregory; Roger McLendon; Darell D Bigner; Hai Yan
Journal:  Neuro Oncol       Date:  2010-05-14       Impact factor: 12.300

2.  Role of senescence and mitotic catastrophe in cancer therapy.

Authors:  Richa Singh; Jasmine George; Yogeshwer Shukla
Journal:  Cell Div       Date:  2010-01-21       Impact factor: 5.130

Review 3.  Mechanisms of DNA damage, repair, and mutagenesis.

Authors:  Nimrat Chatterjee; Graham C Walker
Journal:  Environ Mol Mutagen       Date:  2017-05-09       Impact factor: 3.216

4.  MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2.

Authors:  Jiping Cai; Xiaoyu Liu; Jinwei Cheng; You Li; Xiao Huang; Yuzhen Li; Xiaoye Ma; Hongyu Yu; Huimin Liu; Ruili Wei
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-20       Impact factor: 3.117

Review 5.  Advances in understanding the complex mechanisms of DNA interstrand cross-link repair.

Authors:  Cheryl Clauson; Orlando D Schärer; Laura Niedernhofer
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-10-01       Impact factor: 10.005

6.  Effective elimination of cancer stem cells by a novel drug combination strategy.

Authors:  Shuqiang Yuan; Feng Wang; Gang Chen; Hui Zhang; Li Feng; Lei Wang; Howard Colman; Michael J Keating; Xiaonan Li; Rui-Hua Xu; Jianping Wang; Peng Huang
Journal:  Stem Cells       Date:  2013-01       Impact factor: 6.277

7.  Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.

Authors:  A Peasland; L-Z Wang; E Rowling; S Kyle; T Chen; A Hopkins; W A Cliby; J Sarkaria; G Beale; R J Edmondson; N J Curtin
Journal:  Br J Cancer       Date:  2011-07-05       Impact factor: 7.640

8.  Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo.

Authors:  Longjiang Yang; Juan Du; Jian Hou; Hua Jiang; Jianfeng Zou
Journal:  BMC Cancer       Date:  2011-06-21       Impact factor: 4.430

9.  Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice.

Authors:  Yue Song; Xing Xin; Xingyue Zhai; Zhijun Xia; Keng Shen
Journal:  J Ovarian Res       Date:  2014-12-21       Impact factor: 4.234

10.  Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.

Authors:  Sachita Ganesa; Amrita Sule; Ranjini K Sundaram; Ranjit S Bindra
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.